These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 28814230)
1. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme. Ramezani M; Shamsara J Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230 [TBL] [Abstract][Full Text] [Related]
2. Identification of Non-Zinc Binding Inhibitors of MMP-2 Through Virtual Screening and Subsequent Rescoring. Shamsara J Drug Res (Stuttg); 2018 Sep; 68(9):529-535. PubMed ID: 29614516 [TBL] [Abstract][Full Text] [Related]
3. An integrated structure- and pharmacophore-based MMP-12 virtual screening. Ramezani M; Shamsara J Mol Divers; 2018 May; 22(2):383-395. PubMed ID: 29423648 [TBL] [Abstract][Full Text] [Related]
4. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents. Xie XW; Wan RZ; Liu ZP ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301 [TBL] [Abstract][Full Text] [Related]
5. Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors. Laghezza A; Luisi G; Caradonna A; Di Pizio A; Piemontese L; Loiodice F; Agamennone M; Tortorella P Bioorg Med Chem; 2020 Feb; 28(3):115257. PubMed ID: 31874775 [TBL] [Abstract][Full Text] [Related]
7. Identification of Cuffaro D; Gimeno A; Bernardoni BL; Di Leo R; Pujadas G; Garcia-Vallvé S; Nencetti S; Rossello A; Nuti E Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446276 [TBL] [Abstract][Full Text] [Related]
8. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis. Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology. El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847 [TBL] [Abstract][Full Text] [Related]
10. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors. Di Pizio A; Laghezza A; Tortorella P; Agamennone M ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724 [TBL] [Abstract][Full Text] [Related]
11. Multiple receptor-ligand based pharmacophore modeling and molecular docking to screen the selective inhibitors of matrix metalloproteinase-9 from natural products. Gao Q; Wang Y; Hou J; Yao Q; Zhang J J Comput Aided Mol Des; 2017 Jul; 31(7):625-641. PubMed ID: 28623487 [TBL] [Abstract][Full Text] [Related]
12. Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process. Di Pizio A; Agamennone M; Tortorella P Curr Top Med Chem; 2016; 16(4):449-59. PubMed ID: 26268339 [TBL] [Abstract][Full Text] [Related]
13. In silico study combining docking and QSAR methods on a series of matrix metalloproteinase 13 inhibitors. Xi L; Li S; Yao X; Wei Y; Li J; Liu H; Wu X Arch Pharm (Weinheim); 2014 Nov; 347(11):825-33. PubMed ID: 25363411 [TBL] [Abstract][Full Text] [Related]
14. Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13. Agamennone M; Belov DS; Laghezza A; Ivanov VN; Novoselov AM; Andreev IA; Ratmanova NK; Altieri A; Tortorella P; Kurkin AV ChemMedChem; 2016 Sep; 11(17):1892-8. PubMed ID: 27418256 [TBL] [Abstract][Full Text] [Related]
15. Identification of novel selective MMP-9 inhibitors as potential anti-metastatic lead using structure-based hierarchical virtual screening and molecular dynamics simulation. Kalva S; Agrawal N; Skelton AA; Saleena LM Mol Biosyst; 2016 Jul; 12(8):2519-31. PubMed ID: 27250644 [TBL] [Abstract][Full Text] [Related]
16. Kinetic characterization of 4,4'-biphenylsulfonamides as selective non-zinc binding MMP inhibitors. Santamaria S; Nuti E; Cercignani G; La Regina G; Silvestri R; Supuran CT; Rossello A J Enzyme Inhib Med Chem; 2015 Dec; 30(6):947-54. PubMed ID: 25694065 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552 [TBL] [Abstract][Full Text] [Related]
18. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site. Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810 [TBL] [Abstract][Full Text] [Related]
19. Screening for the selective inhibitors of MMP-9 from natural products based on pharmacophore modeling and molecular docking in combination with bioassay experiment, hybrid QM/MM calculation, and MD simulation. Hou J; Zou Q; Wang Y; Gao Q; Yao W; Yao Q; Zhang J J Biomol Struct Dyn; 2019 Aug; 37(12):3135-3149. PubMed ID: 30079817 [TBL] [Abstract][Full Text] [Related]
20. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor. Senn N; Ott M; Lanz J; Riedl R J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]